Equities research analysts expect that Illumina, Inc. (NASDAQ:ILMN) will announce $692.05 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Illumina’s earnings, with the lowest sales estimate coming in at $680.38 million and the highest estimate coming in at $701.59 million. Illumina reported sales of $607.14 million during the same quarter last year, which would suggest a positive year over year growth rate of 14%. The firm is expected to announce its next earnings results on Tuesday, November 7th.

According to Zacks, analysts expect that Illumina will report full-year sales of $692.05 million for the current financial year, with estimates ranging from $2.67 billion to $2.70 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $3.05 billion per share, with estimates ranging from $2.94 billion to $3.18 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Illumina.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 EPS.

A number of brokerages have recently issued reports on ILMN. Barclays PLC reaffirmed an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a research note on Wednesday, August 9th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target on the stock in a research note on Wednesday, August 9th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Cowen and Company reaffirmed an “outperform” rating and issued a $200.00 price target on shares of Illumina in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. Illumina currently has an average rating of “Hold” and a consensus target price of $177.01.

In related news, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $174.24, for a total value of $25,264.80. Following the sale, the senior vice president now owns 10,646 shares in the company, valued at approximately $1,854,959.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jay T. Flatley sold 22,540 shares of the business’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total value of $4,400,033.40. Following the completion of the sale, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. Insiders sold a total of 167,705 shares of company stock worth $31,544,118 in the last quarter. Company insiders own 1.60% of the company’s stock.

Several hedge funds have recently bought and sold shares of ILMN. Winslow Capital Management LLC purchased a new stake in shares of Illumina in the 2nd quarter valued at $211,584,000. HPM Partners LLC raised its holdings in shares of Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after buying an additional 749,424 shares during the period. Fred Alger Management Inc. raised its holdings in shares of Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares during the period. TIAA CREF Investment Management LLC raised its holdings in shares of Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the period. Finally, Capital World Investors raised its holdings in shares of Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the period. Hedge funds and other institutional investors own 93.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “$692.05 Million in Sales Expected for Illumina, Inc. (ILMN) This Quarter” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/692-05-million-in-sales-expected-for-illumina-inc-ilmn-this-quarter-2.html.

Illumina (ILMN) opened at 209.68 on Friday. Illumina has a 52-week low of $119.37 and a 52-week high of $211.27. The company has a market capitalization of $30.61 billion, a P/E ratio of 42.07 and a beta of 0.81. The stock’s 50 day moving average price is $192.45 and its 200-day moving average price is $178.64.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.